The company said it had agreed to purchase an “ultra-modern” production plant in the western German town of Marburg from Swiss pharmaceutical giant Novartis.
“This acquisition reflects BioNTech’s commitment to particularly developing its production capacity to provide a potential international vaccine after approval or approval,” CHIEF financial officer Sierk Poetting said in a statement.
The Marburg site will increase the production capacity of BioNTech’s COVID-19 vaccine to an additional 750 million doses according to the year, or more than 60 million doses according to the month, “once completely inconsistent with the national one,” he added.
No monetary main points have been revealed.
The agreement is expected to close in the fourth quarter of 2020 and the three hundred Painters of Novartis in it will go on to paint for BioNTech.
Mainz-based BioNTech has partnered with US giant Pfizer to expand a coronavirus vaccine, a new technology based on mRN, a type of genetic clothing never before used to make a vaccine.
They already have a candidate vaccine in the complex Phase 3 trial that is currently being tested on approximately 30,000 volunteers.
To date, 8 other candidate vaccines in the world have reached this stage.
The European Union, the United States and several other countries have already announced primary contracts to protect millions of doses of the imaginable BioNTech-Pfizer vaccine once it has overcome all mandatory regulatory hurdle.
Prior to the acquisition of Marburg, BioNTech announced plans to deliver up to one hundred million doses until the end of 2020 if its vaccine is successful, and 1. 3 billion doses by the end of 2021.
Next year’s figure will now be “significantly” higher, a spokeswoman told the AFP.